7th International Electronic Conference on Medicinal Chemistry
1–30 Nov 2021
Medicinal Chemistry, Pharmacokinetics and Pharmacodynamics, Drug Discovery and Development, Radiopharmaceutical Sciences, Drug Delivery
- Go to the Sessions
- Event Details
On behalf of the conference team of the 7th International Electronic Conference on Medicinal Chemistry, we would like to thank you for your participation by sending your contributions, being posters, slideshows or flash communications. We hope you've enjoyed it!
Claudia Riccardi is currently recipient of a postdoctoral fellowship granted by “Fondazione Umberto Veronesi”, under the supervision of Prof. Daniela Montesarchio. She obtained her degree with honors at the age of 23 in Chemistry and Pharmaceutical Technologies at Federico II University of Naples in 2013. She got her Ph.D. in Chemical Sciences in 2017 and then continued her research activities under the supervision of Prof. Montesarchio with fellowships granted by AIRC (Italian Association for the Research on Cancer). Her research interests are mainly devoted to the design, synthesis, and characterization of Ru(III) and Pt(II) complexes as potential anticancer compounds, as well as G-quadruplex-forming aptamers with potential anticancer or anticoagulant properties. She also studied multifunctional nanosystems incorporating anticancer metal-based drugs and/or aptamers for theranostic applications. She was recipient of the “Salvatore Venuta fellowship 2019” prize in Nanomedicine and of two “Best PhD thesis” prizes. She is coauthor of 32 scientific articles published in the period 2015–2021 in international, peer‐review journals, and of ca. 20 oral and poster communications presented at international and national conferences.
Best Invited Lecture
- Beatriz Berzal-Herranz, Cristina Romero-López et al., "The 3’UTR of WNV genome is an excellent target for antiviral drugs".
Alfredo Berzal-Herranz received his PhD in Molecular Biology from the Autónoma University of Madrid (1990). After a brief stay at the Department of Microbiology, of the University of Uppsala (Sweden), he moved to the Department of Microbiology, College of Medicine of the University of Vermont (USA). In 1993 he returned to Spain, joining the Instituto de Parasitología y Biomedicina “López-Neyra” (IPBLN), located in the city of Granada. The IPBLN belongs to the Spanish National Research Council (CSIC), where he established his own research group and chaired the Department of Molecular Biology. From November 2005 to March 2014 was the Director of the Institute (IPBLN-CSIC). He is the author of about 100 research articles and book chapters and has edited four special research issues. He is or has been a member of the Editorial Board of more than 15 research journals. His research group is currently interested in understanding the structure/function relationship of viral RNA genomes. He is pursuing the identification of the molecular mechanisms used by the RNA viruses to store all necessary genetic information and studying the potential use of genomic RNA structural domains as potential antiviral targets. In addition, his group is interested in the design and characterization of antiviral RNA molecules (Aptamers, antisense, ribozymes).
Cristina Romero-López received her PhD degree in Biochemistry and Molecular Biology by the University of Granada in Nov 2005. The thesis project was focused on developing new RNA-based tools able to interfere with the hepatitis C virus translation. An additional point was to make use of these compounds as molecular tools with the aim of studying the functionality of conserved regions in viral RNA genomes. Since then, she has been working as post-doctoral researcher in the Dr. Berzal-Herranz’s lab, in the Instituto de Parasitología y Biomedicina “López-Neyra” (IPBLN), located in the city of Granada (Spain). Throughout these years, her scientific interest has been focused in the RNA structural biology, moving from the research with small catalytic RNA molecules to current investigations about the functionality of conserved structural domains in viral RNA genomes, as well as their implications in virus progression and infectivity. These studies have promoted the implementation of complex high-throughput techniques for the analysis of the RNA folding. During her scientific career she has participated in eighteen research projects, supported by different national and international agencies. She has published around 50 research manuscripts and book chapters, as well as around 80 communications in national and international meetings. She has supervised six master theses and four graduate theses. Currently, she is a member of the editorial board of different research journals.
One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting
- Marc Le Borgne et al., "Triazole-indole hybrid molecules as antifungal agents: Design, synthesis and biological activity, and beyond".
Marc Le Borgne obtained his Ph.D. in medicinal chemistry under the supervision of Prof. Guillaume Le Baut at the University of Nantes (France) in 1997. He began his research and academic career in the School of Pharmacy at the University of Nantes. In 2008, he moved to the Université Claude Bernard Lyon 1 as a full professor in medicinal chemistry. He is currently a researcher in the Team Small Molecules for Biological Targets (Cancer Research Center of Lyon). His research interests focus on the design and synthesis of bioactive small molecules as anti-infective compounds or kinase-targeted anticancer therapeutic agents. Collaborative work remains at the heart of his quality research work.
One registration seat to an upcoming Simulations Plus workshop
- Radu Tamaian et al., "Rational design of new antipsychotic virtual derivatives with improved ADMET properties and high binding activity".
Principal Investigator at the National Institute for Research and Development for Cryogenic and Isotopic Technologies – ICSI Rm. Vâlcea. My expertise is in bioinformatics and cheminformatics, with a wide research area including computer-aided drug design (CADD), computational (eco)toxicology, in silico nutrigenomics, and blockchain-enabled healthcare. Outside the lab, as the National Contact Point (NCP), I was involved in coordination and support actions for the EU research infrastructures (included in the ESFRI Roadmap) during The 7th Framework Programme of the European Commission.
Welcome from the Chair
Thus, on behalf of the MDPI journal Pharmaceuticals and of the Scientific Committee, I am delighted to welcome you to this 2021 edition.
If you are not familiar with the series, you could ask: why to participate? The answer is simply because this platform aims to bring together scientists from all over the world. It gives students, researchers, and experts the opportunity to share their results and exchange their ideas in medicinal chemistry, in the broad sense of the domain. In addition, there is no need to worry about safety, time off, flights, or hotels. Indeed, this is a virtual event. And guess what? It is, again, absolutely free of charge for authors and visitors as well.
If you are familiar with the series, then, I would like to thank you for your confidence all through the previous years. The success of the series would not have been possible without you, your contribution, and your support.
Ready to join us? Log in, submit your abstract, and enjoy the Conference!
Editor-in-Chief of Pharmaceuticals, Former Head of the Department of Organic Chemistry, University of Mons-UMONS, Belgium
Conference Scientific Committee
Università degli Studi di Urbino Carlo Bo, Urbino, Italy
medicinal chemistry; drug design; cannabinoids; sugar-based surfactants
Dipartimento di Farmacia, Università degli Studi “G. d'Annunzio”, Chieti, Italy
aromatase inhibitors; bioactive compounds; small molecules; anticancer activity; medicinal chemistry; synthesis; drug discovery; PPAR agonists and antagonists; antiproliferative agents; nitric oxide synthase inhibitors
Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, Saint-Ghislain, Belgium
medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs
Dipartimento di Scienze Chimiche e Geologiche, Università di Cagliari, Monserrato, CA, Italy
Irma Lerma Rangel College of Pharmacy, Department of Pharmaceutical Sciences, Texas A&M Health Science Center, Texas A&M University, USA
Departamento de Química e Bioquímica e Centro de Química e Bioquímica, Universidade de Lisboa, Lisboa, Portugal
Universidade Federal do Rio de Janeiro, IPPN, CCS, Rio de Janeiro, Brazil
molecular modeling; computer-aided drug design; bioinformatics; chemoinformatics
Call for participations
- Animal experimentation
- Assay development
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro and in vivo studies
- Lead optimization
- Pharmaceutical analysis
- Structure–activity relationships
Participation in the 7th International Electronic Conference on Medicinal Chemistry is absolutely free of charge for contributors and visitors. Researchers are invited to provide a short abstract (250 words maximum without figure and without references) online at https://www.sciforum.net/login from now until October 18, 2021. A maximum of 3 (three) submissions by each research group (any session combined) will be considered. Acceptance will be notified within a week after submission of the abstract. Then the author(s) will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, at https://ecmc2021.sciforum.net/, on November 1-30, 2021.
Authors will be invited to publish their work as a review or a research article at a discounted price, in a Special Issue of the Journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this Call and will be glad to provide any further information to interested parties. Questions may be addressed to the chairman via e-mail at email@example.com or to the Pharmaceuticals editorial office at firstname.lastname@example.org.
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Laboratório de Química Orgânica e Farmacêutica, Faculdade de Farmácia da Universidade do Porto, Porto, Portugal; CIIMAR, Centro Interdisciplinar de Investigação Marinha e Ambiental, Universidade do Porto, Porto, Portugal
Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA-ARS, 800 Buchanan St., Albany, CA 94710, USA
AGIR, UR 4294, UFR de pharmacie, Université de Picardie Jules Verne, Amiens, France
CQE, Faculdade de Ciências, Universidade de Lisboa, Portugal
Faculté de médecine, Université Laval, Québec, QC, Canada
Université de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000, Nantes, France
Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA
Institute of Parasitology and Biomedicine Lopez-Neyra, CSIC PTS Granada, Granada, Spain
Department of Chemical-Technological Science, State University of Novi Pazar, Vuka Karadžiča bb, 36300 Novi Pazar, Serbia
Instructions for Authors
- Researchers interested in attending the Conference must submit an abstract of the work they intend to present (maximum 250 words without figures, without references; keywords must be in alphabetical order), no later than 18 October 2021.
- After the abstract is accepted (1–5 days after receipt of the abstract), the authors will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience.
- Posters must be uploaded as a PDF file using the Poster_template.pptx file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT_template.pptx file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4 file (video) using the PPT_template.pptx file available at the end of this section.
This must be uploaded before 30 October 2021, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the Conference Office.
Contributions will be displayed on the website using Sciforum.net’s proprietary slides viewer and will be accessible at https://sciforum.net/conference/ECMC2021 at the time of the conference. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Contributions must be converted to PDF format before submission, so that they can be easily and automatically converted to be displayed online.
The organization of posters is left completely up to the authors, provided that they use the Conference’s template.
We recommend the following organization for your slideshow or video, using the Conference’s template:
- Length of the presentation: no more than 30 slides
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
The following awards will be offered by our sponsors
Number of Awards Available: 4The open access peer-reviewed Journal Pharmaceuticals will offer one travel grant (400 CHF) to reward the best poster, the best slideshow, the best flash communication, and the best communication. All submissions will be considered, independently of the session (general and round table). The best works will be selected by the members of the Scientific Committee.
Number of Awards Available: 1The open access peer-reviewed Journal Pharmaceuticals will offer one travel grant (500 CHF) to reward the best invited lecture, as selected by the members of the Scientific Committee.
Number of Awards Available: 1One free 1-day hands on/testing using microwaves offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.
Number of Awards Available: 1Simulations Plus, Inc., will offer a single registration seat to an upcoming Simulations Plus workshop (valued at 2,000 USD; e.g. https://www.simulations-plus.com/assets/GIntroOct-Nov2021-FINAL.pdf). Selection will be made by the Company following strict scientific criteria.
Ms. Fendy Fan
Ms. Jennifer Wang
Hielscher Ultrasonics GmbH: High-power ultrasonic processors for liquid processing
Hielscher Ultrasonics specializes in the design, development and production of ultrasonic devices - both for use in laboratories as well as for industrial applications. Due to the outstanding power of the ultrasonic processors and the high quality standards, Hielscher became the world's leading supplier of high performance ultrasonic equipment. The product range of Hielscher Ultrasonics includes ultrasonic devices to / forRead more...
- Synthesis of nanoparticles
- Desaggregieren / Disagglomerating
- Particle Size Reduction (Wet-milling / fine-grinding of micro-and nano-scale particles)
- acceleration of chemical reactions (Sonochemistry)
- Wire cleaning
Helping laboratories to achieve their goals and improve their workflow by providing them with the smartest possible solutions. That is what drives Analis. Thanks to its broad range of lab equipment and lab furniture, Analis can offer both global and integrated solutions in line with your needs. Whether pharma, life science, cell analysis, chemical, medical in vitro diagnosis and industrial QC/QA or R&D, its team of specialists injects its expertise into your applications. A level of professionalism that is also reflected in its after-sales service, application support, technical maintenance and follow-up in its daily quest to secure your satisfaction.
The International Natural Product Sciences Taskforce (INPST) represents an open innovation platform bringing together scientists and key opinion leaders of the natural product scientific research field, as well as members of multiple scientific excellence centers and pharmaceutical-, biotech-, healthtech-, and natural product-related industries.
A pioneer in scholarly open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines. Our 331 diverse, peer-reviewed, open access journals are supported by more than 84,200 academic editors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).
Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.Read more...
With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide.
Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), was founded in January 1991 by a group of researchers from the Commissariat à l’Energie Atomique (CEA). Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated solvents and is the leading supplier of stable isotope-labelled compounds in Europe.Read more...
Eurisotop has a catalog of more than 15,000 chemical compounds covering various fields of application, including proteomics and genomic research, biotechnology discovery, organic synthesis, and pharmaceutical development, as well as manufacturing. We supply the scientific community with stable isotope-labelled chemicals (many of which are produced by Cambridge Isotope Laboratories, Inc.), as well as isotopic gases, NMR solvents, isotopic metals, and clinical trials substrates.
Eurisotop’s team continuously strives to provide customers with high-quality products with a comprehensive product offering. Quality control and production laboratories are equipped with high-performance analytical and spectroscopic instruments and follow rigorous manufacturing procedures. We also take great pride in our history of exceptional customer service.
For specific requirements, our experts will assist you through the process: from the identification of your needs (design of the requested molecule) to after-sales service (technical support).
Pharmaceuticals (ISSN 1424-8247; CODEN: PHARH2) is a peer-reviewed open access journal of medicinal chemistry and related drug sciences, published monthly online by MDPI. The Swiss Chemical Society (SCS) and Academy of Pharmaceutical Sciences (APS) are partners of Pharmaceuticals and their members receive a discount on the article processing charge.
Microwave Technologies Consulting (MTC) specialises in research & process development, and equipment design using microwave (915 MHz, 2.45 GHz and 5.8 GHz) processing technology for applications in the field of biotech, food technology, nanotechnology, medical technology, and the chemical and pharmaceutical industries.Read more...
The focus of MTC activity is to deliver customer-specific industrial solutions, technical, environmental, and economic process benefits. As an independent, scientifically unbiased, and commercially minded company, Microwave Technologies Consulting is a reliable and trusted partner that connects academia and businesses to bring bright ideas and research into the marketplace and to bridge the gap between innovation and commercialization. We are dedicated to understanding and optimising microwave-assisted processes to enable timely process development in line with project demands, from basic R&D approach through to development and life-cycle management.
S1. Opening session
List of Papers (44) Toggle list
List of Papers (21) Toggle list
List of Papers (17) Toggle list
S4. Fighting cancers
List of Papers (28) Toggle list
List of Papers (12) Toggle list
List of Papers (15) Toggle list
Submissions not assigned to panels
S5. Round table on natural products
List of Papers (21) Toggle list
List of Papers (25) Toggle list
List of Papers (9) Toggle list